Editorial
Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions
Abstract
Incretin-based therapy consists of two different classes of medication: glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors. Since the approval of exenatide, the first GLP-1 RA, and sitagliptin, the first DPP-4 inhibitor, by the U.S.
